FDA approves first drug to show survival benefit in liposarcoma
The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Food and Drug Administration (FDA) Regulatory Affairs Source Type: news
More News: Chemotherapy | Food and Drug Administration (FDA) | Liposarcoma | Pharmaceuticals | Sarcomas | Soft Tissue Sarcoma